Genomic Safe Harbors and Nanoparticles for Targeted Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for hematopoietic stem cells face challenges such as limited vector quantities, genotoxicity risks, immune responses, and the lack of a safe and potent delivery vehicle for targeted genetic modifications, particularly for genetic, infectious, and malignant diseases.
Innovation Solution
Identification of genomic safe harbors (GSH) within human hematopoietic stem cells and engineered nanoparticles that deliver all necessary components for genetic editing, including guide RNA and nuclease, with features like thiol linkers and gold nanoparticles to enhance homology-directed repair, and are designed to avoid immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If retroviral vectors are used for gene transfer into HSPC, then gene addition and correction can be achieved, but genotoxicity risks and insertional mutagenesis occur
Solution Approach 1:
The patent applies local quality by targeting specific genomic locations (safe harbors) for gene insertion rather than random integration. The invention identifies and utilizes specific chromosomal regions (such as those near the pseudoautosomal region on chromosome X or chromosome 1) that are permissive for retroviral integration and do not disrupt essential genes. This localized approach concentrates the gene transfer activity at predetermined safe sites, thereby maintaining high gene transfer efficacy while eliminating the harmful effects of random insertional mutagenesis throughout the genome.
2Reliability
If viral vectors are used for gene transfer, then genetic modifications can be achieved, but immune responses are induced
Solution Approach 1:
The patent applies the extraction principle by removing and eliminating the viral vector component from the gene delivery system. Instead of using infectious viral vectors that trigger immune responses, the invention employs non-viral delivery methods such as liposomal formulations, polymer-based vectors, or direct plasmid DNA transfer. This extraction of the viral element maintains the essential gene transfer capability while completely eliminating the harmful immune responses associated with viral proteins and nucleic acids.
3Reliability
If therapeutic vectors are administered, then gene therapy can be provided, but limited vector quantities create a bottleneck
Solution Approach 1:
The patent applies parameter changes by fundamentally altering the physical and chemical parameters of the delivery vehicle. Instead of using viral vectors with limited titers and complex purification requirements, the invention employs synthetic non-viral carriers (such as liposomes, polyplexes, or nucleic acid conjugates) that can be produced at much higher concentrations and scaled more easily. This change in the fundamental parameters of the delivery system enables massive increases in vector quantity availability while maintaining therapeutic efficacy through optimized formulation chemistry.
4Reliability
If current gene therapy methods are used, then genetic corrections can be achieved, but complex manufacturing processes are required
Solution Approach 1:
The patent applies segmentation by dividing the gene therapy system into separate, modular components that can be independently optimized and manufactured. The invention separates the genetic payload (correcting nucleic acid sequences) from the delivery vehicle (simplified non-viral carriers), allowing each component to be produced through independent, less complex processes. This modular segmentation enables parallel manufacturing of multiple therapy variants using the same simplified platform, dramatically reducing overall manufacturing complexity while maintaining genetic correction accuracy.
Data Source
AI summary
Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.